Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +26.40p +1.61% 1,665.00p 1,663.60p 1,664.20p 1,672.00p 1,645.40p 1,646.60p 10,868,251 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.6 -

GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial

02/05/2019 5:59pm

Dow Jones News

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more Glaxosmithkline Charts.
   By Adria Calatayud 

GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) said Thursday that their Trelegy Ellipta inhaler, which treats patients living with uncontrolled asthma, met the primary endpoint in a phase 3 study.

The pharmaceutical companies said the study showed a statistically significant improvement in lung function at 24 weeks of once-daily treatment with Trelegy Ellipta compared with other medication.

However, the drug didn't achieve a statistically significant reduction in the annualized rate of asthma exacerbations, which was the secondary endpoint of the trial, the companies said.


Write to Adria Calatayud at


(END) Dow Jones Newswires

May 02, 2019 12:44 ET (16:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190717 03:03:26